An Investigation into the Potential of SarAr for Use in 64Cu Radioimmunotherapy

Nadine Di Bartolo; Suzanne V. Smith; Eric Hetherington; Alan Sargeson

doi:10.1071/CH09369

RESEARCH FRONT

Previous Next Contents Vol 62(10)

An Investigation into the Potential of SarAr for Use in ⁶⁴Cu Radioimmunotherapy

Nadine Di Bartolo ^A ^B , Suzanne V. Smith ^A ^D , Eric Hetherington ^A and Alan Sargeson ^B ^C

+ Author Affiliations

- Author Affiliations

^A Australian Nuclear Science and Technology Organisation (ANSTO), PMB 1, Menai, NSW 2234, Australia.

^B Research School of Chemistry, Australian National University, Canberra, ACT 0200, Australia.

^C Deceased.

^D Corresponding author. Email: svs@ansto.gov.au

Australian Journal of Chemistry 62(10) 1261-1270 https://doi.org/10.1071/CH09369
Submitted: 30 June 2009 Accepted: 13 August 2009 Published: 13 October 2009

Abstract

The B72.3 monoclonal antibody was radiolabelled with ¹²³I, and with ¹¹¹In and ⁶⁴Cu, using DTPA and SarAr, respectively. Their biodistribution in tumour-bearing nude mice was used to calculate the dosimetry of their respective therapeutic analogue, using ¹³¹I, ⁹⁰Y, ⁶⁷Cu, and ⁶⁴Cu. Two dosimetry models were used: one using the classical approach and a second model that takes into consideration the chemical stability of the radiolabelling methods employed and the biological clearance of each radioimmunoconjugate. Results clearly show that the ⁶⁴Cu-SarAr-B72.3 could be used as a therapeutic agent and, theoretically, be at least as effective as any of the other therapeutic radionuclides currently studied, such as ¹³¹I, ⁹⁰Y, and ⁶⁷Cu.

Acknowledgements

Alan was my teacher, my mentor, my colleague and my very dear friend. A genuine person who lived and represented for me the best that a scientist and human could offer their communities; demonstrating qualities that we all recognise in various leaders but rarely capture in one individual.

References

An Investigation into the Potential of SarAr for Use in 64Cu Radioimmunotherapy

Abstract

Acknowledgements

Subscriber Login

An Investigation into the Potential of SarAr for Use in ⁶⁴Cu Radioimmunotherapy